CompletedNCT01905436

Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia

Studying Filariasis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Washington University School of Medicine
Principal Investigator: Gary J Weil, MD
Washington University School of Medicine
Intervention: Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration(drug)
Enrollment: 21862 enrolled
Eligibility: 5 years · All sexes
Timeline: 2012 – 2021

Study locations (1)

Liberian Institute of Biomedical Research, Charlesville, Margibi County, Liberia

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01905436 on ClinicalTrials.gov

Other trials for Filariasis

Additional recruiting or active studies for the same condition.

RECRUITINGNCT00001230
Host Response to Infection and Treatment in Filarial Diseases
National Institute of Allergy and Infectious Diseases (NIAID)

See all trials for Filariasis →

← Back to all trials